Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma AB (”Ascelia Pharma”) has resolved to issue and immediately thereafter repurchase 397,641 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020.
Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma has resolved on a directed issue of 397,641 series C shares to Svenska Handelsbanken AB. The subscription price per share amounts to SEK 1, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 397,641 series C shares from Svenska Handelsbanken AB at a price corresponding to the subscription price.
The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of matching shares and performance shares to employees within Ascelia Pharma who are participating in the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020, and, in terms of liquidity, to hedge payments of future social security contributions related to LTI 2020. Allotment of matching shares and performance shares in LTI 2020 shall take place within 30 days from the publication of the financial report for the period June – September 2023.
Since previously, Ascelia Pharma holds 510,545 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.
ASCELIA PHARMA AB 
